Fresenius stock trades at EUR 42.84 with EUR 24.2 billion value

Published on 10/12/2026 at 14:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fresenius stock was priced at EUR 42.84 on October 12, 2026 versus EUR 42.35. The Xetra close implies a plus 1.16 percent move.

Key points in brief

Fresenius stock was trading at EUR 42.84 at Lang & Schwarz on October 12, 2026 at 2:07 p.m. CEST.
The price was plus 1.16 percent versus the Xetra close of EUR 42.35 on October 9, 2026.
Market capitalization was EUR 24.2 billion, with a 52-week range of EUR 35.11 to EUR 52.96.
Jefferies maintained a Buy rating and a EUR 55.00 price target dated October 2, 2026.

Fresenius SE – Fotorealistisch: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht — Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht, Illustration mit AI erstellt.

Fresenius (ISIN DE000FRE5EN2) was trading at EUR 42.84 at Lang & Schwarz on October 12, 2026 at 2:07 p.m. CEST, up EUR 0.49 or 1.16 percent versus the Xetra close of EUR 42.35 on October 9, 2026. The healthcare group had a market capitalization of EUR 24.2 billion as of October 12, 2026.

Stock remains below yearly high

The current price stood EUR 10.12 below the 52-week high of EUR 52.96 and EUR 7.73 above the 52-week low of EUR 35.11. That places the stock 19.11 percent below its high and 22.02 percent above its low, keeping the quote in the middle section of its annual range rather than at an extreme.

Trading volume was 215,497 shares at the finance quote timestamp, compared with an average volume of 996,443 shares. Current turnover therefore represented 21.63 percent of the average, a market-activity comparison that adds context to the intraday price move.

Valuation and analyst target

Fresenius traded at a price-to-earnings ratio of 15.60 and carried a dividend yield of 0.02 percent in the October 12, 2026 quote. The combination gives the price report a valuation anchor beyond the daily percentage move.

wallstreetONLINE reported that Jefferies maintained a Buy rating and a EUR 55.00 price target in a study dated October 2, 2026. The target lies 28.38 percent above the Lang & Schwarz price of EUR 42.84.

Comparison with peers

Fresenius (Xetra, EUR): plus 1.16 percent, P/E 15.60, market capitalization EUR 24.2 billion

Siemens Healthineers (Xetra, EUR): plus 0.66 percent, P/E 19.90, market capitalization EUR 44.1 billion

Sartorius (Xetra, EUR): plus 1.19 percent, P/E 89.93, market capitalization EUR 17.7 billion

Next reporting date

Fresenius lists November 4, 2026 as the date for its third-quarter 2026 results and conference call. The date gives the market a clearly defined next reporting point after the October 12 price snapshot.

Market position in figures

Fresenius combines a EUR 42.84 quote with a 15.60 price-to-earnings ratio and a EUR 24.2 billion market capitalization. Its 19.11 percent distance from the 52-week high remains the clearest placement measure for the current price.

At Lang & Schwarz, Fresenius was trading at EUR 42.84 on October 12, 2026 at 2:07 p.m. CEST, plus 1.16 percent versus the Xetra close of October 9, 2026 at EUR 42.35. The further course of trading is shown by the continuously updated real-time quote of Fresenius stock.